{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:01:16Z","timestamp":1792213276088,"version":"4.4.0"},"reference-count":65,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"DOI":"10.3389\/fmed.2017.00141","type":"journal-article","created":{"date-parts":[[2017,8,21]],"date-time":"2017-08-21T10:38:26Z","timestamp":1503311906000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Vasopressin Receptor Antagonists in Hyponatremia: Uses and Misuses"],"prefix":"10.3389","volume":"4","author":[{"given":"Helbert","family":"Rondon-Berrios","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Berl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.7326\/0003-4819-102-2-164","article-title":"Hyponatremia: a prospective analysis of its epidemiology and the pathogenetic role of vasopressin","volume":"102","author":"Anderson","year":"1985","journal-title":"Ann Intern Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/ndt\/gfi082","article-title":"Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management","volume":"21","author":"Hoorn","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.amjmed.2009.01.027","article-title":"Mortality after hospitalization with mild, moderate, and severe hyponatremia","volume":"122","author":"Waikar","year":"2009","journal-title":"Am J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1001\/archinternmed.2009.513","article-title":"Impact of hospital-associated hyponatremia on selected outcomes","volume":"170","author":"Wald","year":"2010","journal-title":"Arch Intern Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-009-1692-0","article-title":"Incidence and prognosis of dysnatremias present on ICU admission","volume":"36","author":"Funk","year":"2010","journal-title":"Intensive Care Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1007\/s12630-010-9309-1","article-title":"Characterization of intensive care unit acquired hyponatremia and hypernatremia following cardiac surgery","volume":"57","author":"Stelfox","year":"2010","journal-title":"Can J Anaesth"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.2215\/CJN.00170115","article-title":"Mild chronic hyponatremia in the ambulatory setting: significance and management","volume":"10","author":"Rondon-Berrios","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/eurheartj\/ehl542","article-title":"Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry","volume":"28","author":"Gheorghiade","year":"2007","journal-title":"Eur Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/MCG.0b013e3181aabbcd","article-title":"Serum sodium predicts prognosis in critically ill cirrhotic patients","volume":"44","author":"Jenq","year":"2010","journal-title":"J Clin Gastroenterol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1053\/j.ajkd.2011.08.029","article-title":"Hyponatremia in hospitalized cancer patients and its impact on clinical outcomes","volume":"59","author":"Doshi","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/jhm.2168","article-title":"Association of serum sodium with morbidity and mortality in hospitalized patients undergoing major orthopedic surgery","volume":"9","author":"Mc Causland","year":"2014","journal-title":"J Hosp Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1161\/CIRCULATIONAHA.111.065391","article-title":"Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure","volume":"125","author":"Kovesdy","year":"2012","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1053\/j.ajkd.2013.02.367","article-title":"Hyponatremia, mineral metabolism, and mortality in incident maintenance hemodialysis patients: a cohort study","volume":"62","author":"Nigwekar","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1053\/j.ajkd.2011.07.013","article-title":"Predialysis serum sodium level, dialysate sodium, and mortality in maintenance hemodialysis patients: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"59","author":"Hecking","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B15","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/ndt\/gfu040","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia","volume":"29","author":"Spasovski","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations","volume":"126","author":"Verbalis","year":"2013","journal-title":"Am J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/ki.2015.4","article-title":"Current treatment practice and outcomes. Report of the hyponatremia registry","volume":"88","author":"Greenberg","year":"2015","journal-title":"Kidney Int"},{"key":"B18","doi-asserted-by":"publisher","first-page":"537.e9","DOI":"10.1016\/j.amjmed.2015.11.005","article-title":"Diagnosing and treating the syndrome of inappropriate antidiuretic hormone secretion","volume":"129","author":"Verbalis","year":"2016","journal-title":"Am J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"446","DOI":"10.4158\/EP.12.4.446","article-title":"Hyponatremia, fluid-electrolyte disorders, and the syndrome of inappropriate antidiuretic hormone secretion: diagnosis and treatment options","volume":"12","author":"Siragy","year":"2006","journal-title":"Endocr Pract"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"Oral tolvaptan is safe and effective in chronic hyponatremia","volume":"21","author":"Berl","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.ejim.2015.10.020","article-title":"The syndrome of inappropriate antidiuretic hormone secretion: distribution and characterization according to etiologies","volume":"26","author":"Shepshelovich","year":"2015","journal-title":"Eur J Intern Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5301\/tj.5000257","article-title":"Hyponatremia in cancer patients","volume":"101","author":"Platania","year":"2015","journal-title":"Tumori"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(11)60165-7","article-title":"Small-cell lung cancer","volume":"378","author":"van Meerbeeck","year":"2011","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/cncr.28468","article-title":"Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety","volume":"120","author":"Salahudeen","year":"2014","journal-title":"Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/cam4.805","article-title":"Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials","volume":"6","author":"Gralla","year":"2017","journal-title":"Cancer Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1093\/annonc\/mdr431","article-title":"High sensitivity to tolvaptan in paraneoplastic syndrome of inappropriate ADH secretion (SIADH)","volume":"22","author":"Kenz","year":"2011","journal-title":"Ann Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/1471-2466-13-55","article-title":"A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan","volume":"13","author":"Petereit","year":"2013","journal-title":"BMC Pulm Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1749-6632.1993.tb55541.x","article-title":"Tumor biosynthesis of vasopressin and oxytocin","volume":"689","author":"North","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3816\/CLC.2007.n.008","article-title":"Tumor lysis associated with sudden onset of syndrome of inappropriate antidiuretic hormone secretion","volume":"8","author":"Saintigny","year":"2007","journal-title":"Clin Lung Cancer"},{"key":"B31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1159\/000106456","article-title":"Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia","volume":"27","author":"Zeltser","year":"2007","journal-title":"Am J Nephrol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1053\/j.ajkd.2010.01.013","article-title":"Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis","volume":"56","author":"Rozen-Zvi","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"B33","doi-asserted-by":"publisher","first-page":"977.e1","DOI":"10.1016\/j.amjmed.2011.04.028","article-title":"Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia","volume":"124","author":"Jaber","year":"2011","journal-title":"Am J Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e3310","DOI":"10.1097\/MD.0000000000003310","article-title":"Efficacy and safety of vasopressin receptor antagonists for euvolemic or hypervolemic hyponatremia: a meta-analysis","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40261-016-0470-3","article-title":"The efficacy and safety of tolvaptan in patients with hyponatremia: a meta-analysis of randomized controlled trials","volume":"37","author":"Li","year":"2017","journal-title":"Clin Drug Investig"},{"key":"B36","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/cen.13315","article-title":"A systematic review of known interventions for the treatment of chronic nonhypovolaemic hypotonic hyponatraemia and a meta-analysis of the vaptans","volume":"86","author":"Bhandari","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1007\/s00520-017-3638-3","article-title":"Euvolemic hyponatremia in cancer patients. Report of the hyponatremia registry: an observational multicenter international study","volume":"25","author":"Burst","year":"2017","journal-title":"Support Care Cancer"},{"key":"B38","volume-title":"Adverse Event Detailed Report on File 2015\u20131112","year":"2015"},{"key":"B39","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.beem.2016.02.004","article-title":"Vasopressin receptor antagonists: characteristics and clinical role","volume":"30","author":"Rondon-Berrios","year":"2016","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B40","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S1043-2760(03)00048-1","article-title":"Hyponatremia in patients with central nervous system disease: SIADH versus CSW","volume":"14","author":"Palmer","year":"2003","journal-title":"Trends Endocrinol Metab"},{"key":"B41","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1681\/ASN.2007101118","article-title":"Cerebral salt wasting versus SIADH: what difference?","volume":"19","author":"Sterns","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1210\/jc.2013-3032","article-title":"Hyponatremia following mild\/moderate subarachnoid hemorrhage is due to SIAD and glucocorticoid deficiency and not cerebral salt wasting","volume":"99","author":"Hannon","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B43","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1210\/jc.2013-4289","article-title":"Hyponatremia with intracranial disease: not often cerebral salt wasting","volume":"99","author":"Verbalis","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"B44","first-page":"83","article-title":"Conivaptan: evidence supporting its therapeutic use in hyponatremia","volume":"4","author":"Li-Ng","year":"2009","journal-title":"Core Evid"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf"},{"key":"B47","unstructured":"Samsca (Tolvaptan): Drug Safety Communication \u2013 FDA Limits Duration and Usage due to Possible Liver Injury Leading to Organ Transplant or Death2013"},{"key":"B48","unstructured":"Otsuka Announces Results of Phase 3 Data on Tolvaptan Under Development for ADPKD in U.S2017"},{"key":"B49","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/0885066610397016","article-title":"Hyponatremia and the use of vasopressin receptor antagonists in critically ill patients","volume":"27","author":"Lehrich","year":"2012","journal-title":"J Intensive Care Med"},{"key":"B50","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1399-0012.1998.tb01102.x","article-title":"Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis","volume":"12","author":"Abbasoglu","year":"1998","journal-title":"Clin Transplant"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1097\/00007890-198912000-00023","article-title":"Pontine and extrapontine myelinolysis following liver transplantation. Relationship to serum sodium","volume":"48","author":"Wszolek","year":"1989","journal-title":"Transplantation"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.6002\/ect.2015.0209","article-title":"Short-term, low-dose use of tolvaptan as a bridge therapy to expedite liver transplant for severe hyponatremic, cirrhotic patients with high model for end-stage liver disease scores","author":"Lenci","year":"2015","journal-title":"Exp Clin Transplant"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14317","article-title":"Prevention of the osmotic demyelination syndrome after liver transplantation: a multidisciplinary perspective","author":"Crismale","year":"2017","journal-title":"Am J Transplant"},{"key":"B54","unstructured":"Rondon-BerriosH Urea in the Treatment of Hyponatremia2017"},{"key":"B55","doi-asserted-by":"publisher","first-page":"c168","DOI":"10.1159\/000338539","article-title":"Long-term treatment of hyponatremic patients with nephrogenic syndrome of inappropriate antidiuresis: personal experience and review of published case reports","volume":"120","author":"Vandergheynst","year":"2012","journal-title":"Nephron Clin Pract"},{"key":"B56","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/ki.2011.78","article-title":"Vaptans are not the mainstay of treatment in hyponatremia: perhaps not yet","volume":"80","author":"Gross","year":"2011","journal-title":"Kidney Int"},{"key":"B57","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1053\/j.ajkd.2015.12.024","article-title":"Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT)","volume":"67","author":"Verbalis","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"key":"B59","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/17482940701210179","article-title":"Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (ACTIV in CHF) trial","volume":"9","author":"Rossi","year":"2007","journal-title":"Acute Card Care"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"B61","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","article-title":"Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan","volume":"19","author":"Hauptman","year":"2013","journal-title":"J Card Fail"},{"key":"B62","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3810\/hp.2012.02.942","article-title":"Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials","volume":"40","author":"Dasta","year":"2012","journal-title":"Hosp Pract (1995)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"328","DOI":"10.2146\/ajhp100217","article-title":"Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure","volume":"68","author":"Cyr","year":"2011","journal-title":"Am J Health Syst Pharm"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.clinthera.2014.07.010","article-title":"Cost-effectiveness of tolvaptan for euvolemic or hypervolemic hyponatremia","volume":"36","author":"Lee","year":"2014","journal-title":"Clin Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12902-016-0104-z","article-title":"Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden","volume":"16","author":"Jamookeeah","year":"2016","journal-title":"BMC Endocr Disord"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2017.00141\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T23:44:48Z","timestamp":1750808688000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fmed.2017.00141\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,21]]},"references-count":65,"alternative-id":["10.3389\/fmed.2017.00141"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2017.00141","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,21]]},"article-number":"141"}}